Abstract:Abstract Introduction: Trimethylation of Histone 3 Lysine 27 (H3K27) is widely understood to be a mark associated with gene repression and linked to gene silencing during development. Neuroblastoma, a developmental pediatric extracranial solid malignancy, has a relatively silent mutational landscape. Therefore, epigenetic modifications, including H3K27me3 mediated repression, could explain underlying developmental origins and the wide clinical heterogeneity observed. While previous studies have focused on the role of distinct super enhancer histone marks and their core regulatory circuits, less is understood about repressive control. We aimed to therefore investigate the role of H3K27me3-mediated repression in Neuroblastoma patients. Methods: Genome-wide H3K27me3 ChIP-Seq profiles were obtained from 48 diagnostic tissue biopsies covering all clinical and molecular patient subgroups. Transcriptome sequencing, ChIP-Seq of additional histone marks and WES/WGS was also performed on the same samples and on a panel of Neuroblastoma cell line models, with multiomics integrative analysis to validate findings. HMCAN, deepTools, DiffBind and ROSE packages were used to analyze the ChIP-seq data. Results: A comparison of H3K27me3 regions across all patient ChIP-Seq profiles, identified commonly repressed genes specific to Neuroblastoma. These genes are enriched in development and differentiation pathways, with significantly lower RNA expression levels than other publicly available pediatric tumor datasets. When compared to publicly available single cell RNAseq of the healthy adrenal medulla, we can further highlight a potential role of H3K27me3-mediated repression in regulating cell lineage commitment and differentiation ability. In addition, we identified that patient samples cluster into their clinical subgroups based on H3K27me3 patterns and differentially repressed genes, specifically between MYCN-amplified and non-amplified high-risk groups. A CRISPR screen to further validate the functional role of these repressed genes is being carried out. Conclusions: To our knowledge, this study shows for the first time that understanding of H3K27me3 mediated repression in Neuroblastoma, can uncover new insights into both disease development and clinical subclassifications. This knowledge will be important when considering future potential novel treatment options. Citation Format: Charlotte Butterworth, Alexandra Saint-Charles, Yasmine Iddir, Jaydutt Bhalshankar, Angela Bellini, Charles Bobin, Elisa Wecht, Young-Gyu Park, Caroline Louis, Virginie Raynal, Dominique Plantaz, Hervé Sartelet, Valérie Combaret, Gaelle Pierron, Isabelle Janoueix-Lerosey, Kai-Oliver Henrich, Olivier Delattre, Frank Westermann, Gudrun Schleiermacher. Study of spatial and temporal epigenetic heterogeneity in neuroblastoma suggests role of H3K27me3-mediated repression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2847.

Supplementary Dataset 4 from WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma

Data from WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma

Wdr5 Supports An N-Myc Transcriptional Complex That Drives A Protumorigenic Gene Expression Signature In Neuroblastoma

WDR5 Facilitates Recruitment of N-MYC to Conserved WDR5 Gene Targets in Neuroblastoma Cell Lines

WDR5-Myc Axis Promotes the Progression of Glioblastoma and Neuroblastoma by Transcriptional Activating CARM1.

Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma

Supplementary Figure S6 G-K from Drugging MYCN Oncogenic Signaling Through the MYCN-PA2G4 Binding Interface

Abstract PR06: the Enhancer Landscape Involves a Core Noncoding RNA Protein Interaction Network Forc-Mycexpression

Overexpression of WD Repeat Domain 5 Associates with Aggressive Clinicopathological Features and Unfavorable Prognosis in Head Neck Squamous Cell Carcinoma.

Supplementary Figure 2 from Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies

Supplementary Data from the RNA M6a Reader YTHDF2 Maintains Oncogene Expression and is a Targetable Dependency in Glioblastoma Stem Cells

Supplementary Figure 1 from Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies

Supplementary Figure from NSD2 is Recruited Through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma

Supplementary Figure S6 A-F from Drugging MYCN Oncogenic Signaling Through the MYCN-PA2G4 Binding Interface

Abstract 2847: Study of spatial and temporal epigenetic heterogeneity in neuroblastoma suggests role of H3K27me3-mediated repression

Myc Activation Through Enhancer Hijacking Or Focal Enhancer Amplification Drives A Subset Of High-Risk Pediatric Neuroblastoma

The Long Noncoding RNA Lncnb1 Promotes Tumorigenesis by Interacting with Ribosomal Protein RPL35

Additional File 2: Figure S1. of A Positive Feedback Loop Involving the Wnt/Î˛-catenin/MYC/Sox2 Axis Defines a Highly Tumorigenic Cell Subpopulation in ALK-positive Anaplastic Large Cell Lymphoma

Supplementary Data from Microrna Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies

Supplementary Table 1 from Progressive Chromatin Repression and Promoter Methylation of <i>CTNNA1</i> Associated with Advanced Myeloid Malignancies

JMJD6 is a Tumorigenic Factor and Therapeutic Target in Neuroblastoma